* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download PowerPoint File
Survey
Document related concepts
Electrocardiography wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Hypertrophic cardiomyopathy wikipedia , lookup
Heart failure wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Myocardial infarction wikipedia , lookup
Cardiac surgery wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Cardiac arrest wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Ventricular fibrillation wikipedia , lookup
Transcript
ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then oral spironolactone 25 mg daily for 6 months (n = 802) vs. control (n = 801). Results (p = 0.97) 11.8 12.2 % • Death, resuscitated cardiac arrest, significant ventricular arrhythmia, indication for implantable defibrillator, or new/worsening heart failure at 6 months: 11.8% of the spironolactone group vs. 12.2% of the control group (p = 0.97) Conclusions • Among patients with MI without heart failure, an early aldosterone antagonist (IV potassium canrenoate/oral spironolactone) was not beneficial at reducing adverse cardiac events compared with control Spironolactone Control Presented by Dr. Gilles Montalescot at ESC 2015